期刊文献+
共找到35,474篇文章
< 1 2 250 >
每页显示 20 50 100
Liver Function Tests in Patients of Acute Leukemia before and after Induction Chemotherapy 认领
1
作者 Tahmidul Islam A. K. M. Shahidur Rahman +7 位作者 Md. Kamrul Hasan Ferdous Jahan Manik Chandra Mondal Sheuly Ferdoushi Sabrina Alam Mohammad Kamrul Ahsan Jannatut Tasnim Sharaban Tohura 《生物科学与医学(英文)》 2020年第2期110-121,共12页
Background: Patients of acute leukemia require careful assessment of liver function prior to start chemotherapy to determine which drugs may be appropriate or to be modified. Post chemotherapy abnormalities of liver f... Background: Patients of acute leukemia require careful assessment of liver function prior to start chemotherapy to determine which drugs may be appropriate or to be modified. Post chemotherapy abnormalities of liver function tests may be due to drugs or due to disease process itself. Objective: To evaluate the status of liver function in acute leukemia patients before and after induction chemotherapy. Methodology: This was a prospective cross-sectional study conducted in the Department of Biochemistry, Dhaka Medical College, Dhaka, Bangladesh from January 2017 to December 2017 on fifty (50) newly diagnosed patients of acute leukemia who fulfilled the selection criteria. Blood samples for serum total bilirubin, alanine transaminase (ALT) and aspartate transaminase (AST) were collected before chemotherapy (Day 1) and after induction chemotherapy on 14th day and 30th day. Serum ALT and AST were measured by kinetic method and serum total bilirubin was measured by DMSO method. Data were analyzed and compared by statistical tests. Result: In this study, the mean level of serum total bilirubin before chemotherapy at day 1 was 0.89 ± 0.64 mg/dl. It was significantly (p Conclusion: It is concluded that serum total bilirubin, ALT and AST increase in response to chemotherapeutic drugs during treatment of acute leukemia. 展开更多
关键词 Acute LEUKAEMIA ALANINE TRANSAMINASE (ALT) ASPARTATE TRANSAMINASE (AST) BILIRUBIN CHEMOTHERAPY
在线阅读 免费下载
The Prognostic and Curative Benefits of Primary Tumor Resection versus No Resection in Stage IV Colorectal Cancer: A Comparative Study 认领
2
作者 Ibtsam Shehta Harera Taha A. Baiomy +5 位作者 Ahmed A. Obaya Shady E. Shaker Amr Samir Ahmed M. Elsayed Enas Mahmoud Hamed Loay M. Gertallah 《外科学(英文)》 2020年第3期39-49,共11页
Background: Colorectal cancer (CRC) who is initially diagnosed with single or multiple synchronous distant metastases has an incidence of about 20% of all CRC patients. There is a controversy regarding the role of res... Background: Colorectal cancer (CRC) who is initially diagnosed with single or multiple synchronous distant metastases has an incidence of about 20% of all CRC patients. There is a controversy regarding the role of resection of the primary tumors in those patients. The aim of this study was to explore the prognostic roles and survival advantages of surgical excision of the primary colonic tumor in patients with CRC who are primarily diagnosed with distant metastases. Patients and Methods: We included forty patients who were diagnosed initially with stage IV CRC. We have divided the included patients into two categories the first one included 20 patients that underwent surgical excision of the primary cancer followed by administration of chemotherapy and the remaining 20 patients were initially given chemotherapy without excision of the cancer. We followed patients for 24 months to detect progression, response to chemotherapy, recurrence free survival and overall survival rates. Results: There is statistically significant difference between patients underwent different initial management techniques regarding N stage of the tumor (p = 0.039), response to chemotherapy (p = 0.048), occurrence of relapse (p = 0.022), disease free survival (DFS) (p = 0.027) or overall survival (OS) rates (p = 0.001) (DFS and OS were significantly higher among patients who received initial surgical management. Primary surgical removal of the tumor improved OS rate by 8 months (p = 0.001). Conclusion: Surgical removal of the primary malignancy in mCRC patients before chemotherapy administration improves patients’ survival rates and response to chemotherapy that lead to a better prognosis. 展开更多
关键词 METASTATIC CRC (mCRC) Surgical RESECTION Chemotherapy Survival
在线阅读 免费下载
Administration of Chemotherapy in University Clinical Center of Kosova by Nurses 认领
3
作者 Vlora Ejupi Shqipe Tahiri Idriz Sopjani 《护理学期刊(英文)》 2020年第5期513-525,共13页
Policy development on chemotherapy management has increased the demand for deeper knowledge in this field. In this way, there was a need to identify, recognize the consumption trends of chemotherapeutic and prioritize... Policy development on chemotherapy management has increased the demand for deeper knowledge in this field. In this way, there was a need to identify, recognize the consumption trends of chemotherapeutic and prioritize the interest of regulatory bodies, as well as to design programs for health education. In 1978 for the first time in Kosovo, a Hematology Department was established within the Internal Diseases Clinic by Dr. Shaban Geci. In 2013 it became a Clinic of Hematology. The Department of Clinical Hematology deals with the diagnosis of hematologic and hematopoietic diseases including erythrocytes, leukocytes, platelets as well as malignant diseases. Within the department is also the location for puncture and biopsy of the bone marrow as well as for ultrasonography. Methods: The study was prospective and was conducted at University Clinical Center of Kosova (UCCK) and is based on an anonymous survey designed specifically for this purpose. The subject of the analysis was the available space for hospitalization and administration of chemotherapeutic at UCCK, the existence or not of written protocols, and available technical equipment. Results: Respondents were asked how many nurses handle the administration of cytostatic at the clinic where they work. 48% of respondents state that 1 - 5 nurses deal with cytostatic administration, 52% of respondents say 1 - 15 nurses deal with cytostatic administration, while alternatives 6 - 10 nurses and 16 and more nurses were not selected by no respondents. 展开更多
关键词 UCCK CHEMOTHERAPY Nurses STANDARDS Cancer
在线阅读 免费下载
Prognostic Significance of BCL2 Protein in Diffuse Large Cell Lymphoma of Head and Neck;Relation to Response to Chemotherapy 认领
4
作者 Heba A. Elhendawy Afaf T. Ibrahiem +1 位作者 Hoda S. Elmahdi Amany M. Omar 《病理学期刊(英文)》 2020年第2期76-92,共17页
Diffuse large B cell lymphoma (DLBCL) is a heterogeneous disease that displays a highly variable clinical outcome. It is a neoplasm of large transformed B cells with a diffuse growth pattern. DLBCL is the most common ... Diffuse large B cell lymphoma (DLBCL) is a heterogeneous disease that displays a highly variable clinical outcome. It is a neoplasm of large transformed B cells with a diffuse growth pattern. DLBCL is the most common type of non-Hodgkin’s lymphoma (NHL) (31% of all cases). Approximately half of patients with DLBCL are cured with current chemotherapy regimens. The purpose of this study was to evaluate BCl2 expression in 45 patients diagnosed with DLBCL of head and neck region and correlate the level of its immunohistochemical expression with different clinicopathological variables with emphasis upon patients’ age, gender, nodal or extra-nodal location of lymphoma, patients’ response to chemotherapy, progression-free survival (PFS) and overall survival (OS). A retrospective analysis of 45 patients diagnosed to have DLBCL. A cut off value of ≥ 50% protein expression denoted BCL2 positivity. Out of 45 cases, 36 cases (80%) revealed BCL2 positive expression and 9 cases (20%) were BCL2 negative. We found statistically significant differences in BCL2 expression regarding different patients’ responses to chemotherapy, patients’ OS and PFS (p ≤ 0.05). No statistically significant differences in BCL2 expression regarding the patients’ Ann Arbor clinical stage, age group and tumor site (nodal or extra-nodal, p > 0.05) using the Chi-square test. BCL2 expression was analyzed in relation to 5 years OS and PFS using Kaplan Meier curves and Log Rank test for survival analysis. Cases that demonstrated BCL2 positivity revealed shortened OS and PFS with highly statistically significant differences among the studied variables (p = 0.000). We also found that patients who respond well to the chemotherapeutic regimen had negative BCL2 expression, the differences were statistically significant (p = 0.015). In conclusion, BCL2 expression could be considered a predictor for patients’ chemotherapeutic response, OS and PFS. 展开更多
关键词 DIFFUSE Large B-CELL LYMPHOMA BCL2 CHEMOTHERAPY OS PFS
在线阅读 免费下载
参苓白术散联合化疗对结直肠癌免疫功能及生活质量的影响 认领
5
作者 王浩咏 刘国荣 《中国当代医药》 2020年第9期78-80,84,共4页
目的探讨参苓白术散联合化疗对结直肠癌免疫功能及生活质量的影响。方法选择2016年6月~2018年12月我院收治的84例结直肠癌患者作为研究对象,按照随机数字表法分为观察组和对照组,每组各42例,对照组仅进行常规化疗,观察组在此基础上加服... 目的探讨参苓白术散联合化疗对结直肠癌免疫功能及生活质量的影响。方法选择2016年6月~2018年12月我院收治的84例结直肠癌患者作为研究对象,按照随机数字表法分为观察组和对照组,每组各42例,对照组仅进行常规化疗,观察组在此基础上加服参苓白术散,两组均治疗12周。比较两组治疗前后的免疫功能指标、Karnofsky功能状状态(KPS)积分、治疗过程中的不良反应发生情况以及近期临床疗效。结果两组患者治疗前的免疫功能指标、KPS评分比较,差异无统计学意义(P>0.05);两组患者治疗后的CD3^+、CD4^+、CD4^+/CD8^+均低于治疗前,CD8^+、KPS评分高于治疗前,差异有统计学意义(P<0.05);观察组患者治疗后的CD3^+、CD4^+、CD4^+/CD8^+均低于对照组,CD8^+、KPS评分高于对照组,差异有统计学意义(P<0.05);观察组疾病控制率为88.10%,高于对照组的69.05%,而发生血尿、蛋白尿、白细胞下降、血小板下降、恶心呕吐、腹泻及腹痛的发生率均低于对照组,差异有统计学意义(P<0.05)。结论参苓白术散联合化疗治疗结直肠癌患者效果显著,可有效改善患者的免疫功能,提高生存质量和减轻化疗的不良反应。 展开更多
关键词 参苓白术散 结直肠癌 化疗 免疫功能 生活质量 化疗不良反应
在线阅读 下载PDF
Female Fertility Following Chemotherapy for Breast Cancer: A Descriptive Study of 265 Cases Treated in Yaounde 认领
6
作者 Félix Essiben Ngowa Jean Dupont Kemfang +5 位作者 Aline Nganso Meka Juliette Esther Ngo Um Etienne Atenguena Samuel Ojong Paul Ndom Emile Telesphore Mboudou 《妇产科期刊(英文)》 2020年第1期166-178,共13页
Context: In Cameroon, breast cancer (BC) is usually diagnosed late in the disease course. About a third of women affected are aged less than 40 years. Chemotherapy (CT) could alter ovarian function and thereby comprom... Context: In Cameroon, breast cancer (BC) is usually diagnosed late in the disease course. About a third of women affected are aged less than 40 years. Chemotherapy (CT) could alter ovarian function and thereby compromise future fertility in these women. We therefore described the fertility of women following CT for BC in women treated at the Yaounde General Hospital (YGH). Methods: It was a retrospective, descriptive, cross-sectional study conducted over 8 months, from January to August 2017. We used the files of patients managed for BC from January 2011 to December 2015 in the medical oncology unit of the YGH. Results: We included 265 patients for the study following at least one year of CT. The mean age at the onset of CT was 35.9 ± 6.9 years. Most of the patients had fewer than 2 deliveries (68.3%). Intraductal carcinoma was the most frequent histological lesion (90.6%) and most often diagnosed in advanced stages (73.5%). As per CT, the FAC protocol was the most used (44.5%). The menstrual cycles of the patients were more regular prior to the onset of chemotherapy (89.4% vs. 58.9%), while the mean period of resumption of menstrual activity following cessation of chemotherapy was 6.3 ± 2.0 months. Chemotherapy-related amenorrhoea was observed in 29.1% of patients after 12 months of treatment. More than half of these women (51.3%) complained of a drop in libido and 6.4% achieved pregnancy within 13 months following cessation of chemotherapy. Conclusion: Following chemotherapy for BC, menstrual cycle disorders are more frequent and this can affect the patients’ reproductive potential. Fertility consultations should be integrated into the management plan of such patients. 展开更多
关键词 CHEMOTHERAPY FERTILITY WOMEN of CHILDBEARING Age BREAST Cancer Yaounde
在线阅读 免费下载
肌层浸润性膀胱癌新辅助治疗现状及展望 认领
7
作者 何天基 葛波 《临床泌尿外科杂志》 2020年第2期158-161,共4页
肌层浸润性膀胱癌在膀胱癌中约占25%~30%,目前标准治疗方式为膀胱癌根治术,并需同时行盆腔淋巴结清扫及尿道改流术,但其存在手术难度大、术后并发症多、生活质量差等问题,而新辅助治疗在阻断微转移、降期肿瘤、降低手术难度、减少并发... 肌层浸润性膀胱癌在膀胱癌中约占25%~30%,目前标准治疗方式为膀胱癌根治术,并需同时行盆腔淋巴结清扫及尿道改流术,但其存在手术难度大、术后并发症多、生活质量差等问题,而新辅助治疗在阻断微转移、降期肿瘤、降低手术难度、减少并发症、提高远期生存率等发挥着较大作用,现本文对新辅助治疗在肌层浸润性膀胱癌应用的现状及展望作一综述。 展开更多
关键词 膀胱癌 肌层浸润性膀胱癌 化疗 新辅助治疗
Prediction of Response to Neoadjuvant Chemotherapy in Egyptian Patients with Locally Advanced Breast Cancer: The Evolving Role of Tumour Infiltrating Lymphocytes (TILs) 认领
8
作者 Manal M. El-Mahdy Riham A. Ibrahim +4 位作者 Radwa M. Hamed Mohamaad S. Elkady Walid A. Bayoumy Zeinab M. Elsayed Mai M. Ezz-El-Din 《癌症治疗(英文)》 2020年第4期206-219,共14页
Background & objectives:?Presence of TILs in breast cancer indicates better therapeutic responses to neoadjuvant chemotherapy (NAC), increased pCR and improved outcome. We aim at evaluation of TILs in breast cance... Background & objectives:?Presence of TILs in breast cancer indicates better therapeutic responses to neoadjuvant chemotherapy (NAC), increased pCR and improved outcome. We aim at evaluation of TILs in breast cancer biopsies in correlation with pathological response after NAC in locally advanced breast cancer Methods. This study was conducted at Ain Shams university hospital and Maadi Military hospital in Egypt. 45 Female patients with locally advanced breast cancer were treated with NAC;?pathological response was assessed. Tumours were categorized into: luminal A, luminal B, Her2 enriched and TNBC. Assessment of TILs (CD4 and CD8 lymphocytes) was based on Immuno-Oncology Biomarker Working Group guidelines.?Results:?Tumours were classified into high and low TIL groups using the interquartile range cutoff (29%). High CD4 group showed increased pCR (p?= 0.003) and smaller residual tumours (p?= 0.04). High CD8 group showed a significant association with smaller residual tumours (p?= 0.003). At follow-up of 24-months, CD4 and CD8 high groups showed significantly higher 2-years DFS. The difference between CD4 high and low groups was significant in regards to estrogen receptor status, showing higher levels in hormone-negative tumors (p = 0.029). Patients with Her2 subtype showed higher CD4 (p = 0.007) and CD8 expression (p = 0.018). In CD4 & CD8 low groups, more patients developed local recurrence and distant metastasis (p = 0.025). Conclusion:?We concluded that TILs may predict response to NAC and overall prognosis of breast cancer. The evaluation of TILs in correlation with morphological or genomics-based parameters helps to stratify patients of breast cancer. 展开更多
关键词 BREAST Cancer LYMPHOCYTES NEOADJUVANT Chemotherapy
在线阅读 免费下载
Implementing Appearance-Care Research for Breast Cancer Patient into Routine Clinical Practice 认领
9
作者 Mari Ikeda Hisako Kanai +3 位作者 Misato Osaka Nao Tamai Yukie Takemura Hiromi Sanada 《护理学期刊(英文)》 2020年第3期308-319,共12页
Aims: Research the process of organizational change to understand how interventions such as appearance care can be integrated into daily practice. Background: Typical treatment of breast cancer is surgery, often follo... Aims: Research the process of organizational change to understand how interventions such as appearance care can be integrated into daily practice. Background: Typical treatment of breast cancer is surgery, often followed by chemotherapy. Associated aesthetic ramifications, including hair loss, frequently cause patient distress. Methods: We conducted face-to-face semi-structured hour-long recorded interviews with three nurses. We then analyzed the developmental process according to the core competencies for interprofessional collaborative practice using the thematic content analysis. Results: Nurses worked with interdisciplinary team members with mutual respect and shared values such as concern for patients’ quality of life. Nurses used knowledge of appearance-related side effects combined with beautician-provided coping skills. Intervention involved responsible communication with other health professionals and patients in a team approach. Nurses promoted the developmental process and became program facilitators. Conclusion: This group-intervention program, facilitated by nurses, was integrated into daily practice. Implications for nursing management: Research partnerships between academics, clinical nurses, nurse managers, and beauticians can improve the integration of interventions in routine practice and increase awareness of patients’ needs. 展开更多
关键词 Breast Cancer Chemotherapy Group INTERVENTION INTERPROFESSIONAL COLLABORATIVE Practice Quality of Life
在线阅读 免费下载
Efficacy of Oncoxin-Viusid on the Reduction of Adverse Reactions to Chemotherapy and Radiotherapy in Patients Diagnosed with Cervical Cancer and Endometrial Adenocarcinoma 认领
10
作者 Raiza Ruiz Lorente Daysi Hernández Durán +3 位作者 Jessica García Viamontes Juan Lence Anta Rosa Ortiz Reyes Eduardo Sanz Navares 《癌症治疗(英文)》 2020年第5期276-295,共20页
Introduction: Oncoxin-Viusid (OV) has shown antioxidant, immunomodulatory and anti-tumour capabilities in experimental studies on humans and animal subjects. Acute toxicity of Radiation Therapy (RT) and Chemotherapy (... Introduction: Oncoxin-Viusid (OV) has shown antioxidant, immunomodulatory and anti-tumour capabilities in experimental studies on humans and animal subjects. Acute toxicity of Radiation Therapy (RT) and Chemotherapy (CT) in patients with cervical cancer and endometrial adenocarcinoma impact quality of life and, therefore, outcomes of these therapies. Objective: To identify Oncoxin-Viusid’s efficacy in reducing acute toxicity produced by onco-specific treatments in patients with cervical cancer and endometrial adenocarcinoma. Materials and Methods: A controlled, randomised double-blind phase II clinical trial was performed with a sample size of 63 patients distributed into 2 groups: one receiving the standard treatment plus the Oncoxin-Viusid nutritional supplement (OV group) and another receiving the standard treatment and placebo (P group). The primary efficacy variable is the proportion of secondary disruptions to acute adverse reactions produced by RT and CT. Results: The number of patients suffering adverse events from chemotherapy was 20.6% less in the OV group (70.0%) than in the placebo group (90.6%) (p = 0.04). We recorded consistently normal values of haemoglobin (-6.2 OV group vs -8.3 P group, p = 0.009), platelet count (-17.4 OV group vs -27.6 P group, p = 0.009) and leukocytes (-31.8 OV group vs -41.4 P group, p = 0.025) in the OV group, tolerating 4 more cytostatic doses on average than the placebo group. Significant increase in quality of life (QLQ-30) was registered in the OV group with a large effect size on such issues as emotional and social function (Cohen’s d = 0.9), as well as in the reduction of symptoms like dyspnea 60%, insomnia 15% and anorexia 30% (item CX-2), (Cohen’s d = 0.98), which were higher than the placebo group. Conclusions: OV administration reduces onco-specific adverse events and improves quality of life in patients diagnosed with cervical cancer and endometrial adenocarcinoma undergoing radiation therapy and chemotherapy. 展开更多
关键词 Cervical Cancer ENDOMETRIAL Adenocarcinoma Oncoxin-Viusid RADIOTHERAPY CHEMOTHERAPY ADVERSE Effects
在线阅读 免费下载
Combined intra-arterial chemotherapy and intravitreal melphalan for the treatment of advanced unilateral retinoblastoma 认领
11
作者 Ting-Yi Liang Xiu-Yu Zhu +2 位作者 Xu-Ming Hua Xun-Da Ji Pei-Quan Zhao 《国际眼科杂志:英文版》 SCIE CAS 2020年第2期257-262,共6页
●AIM:To evaluate the efficacy and safety of combined intraarterial chemotherapy(IAC)and intravitreal melphalan(IVM)for the treatment of advanced unilateral retinoblastoma.●METHODS:This retrospective study involved 3... ●AIM:To evaluate the efficacy and safety of combined intraarterial chemotherapy(IAC)and intravitreal melphalan(IVM)for the treatment of advanced unilateral retinoblastoma.●METHODS:This retrospective study involved 30 consecutive eyes from 30 Chinese patients with advanced unilateral retinoblastoma.All patients were initially treated with IAC combined with IVM.The clinical status and complications were recorded at each visit.●RESULTS:The International Intraocular Retinoblastoma Classification groups were D in 23 eyes and E in 7 eyes.All eyes showed severe cloud vitreous seeds at the first visit.The mean number of IAC cycles and intravitreal injections was 3.2(range,3-4)and 6(range,1-14),respectively.The median follow-up time was 29 mo(range,7-36 mo).Treatment success with regression of the retinal tumor and vitreous seeds was achieved in 29 of 30 eyes(96.7%).Globe salvage was attained in 93.3%(28/30)eyes,and enucleation(n=2)was per formed due to neovascular glaucoma and persistent vitreous hemorrhage.Complications included retinal pigment epithelium(RPE)atrophy(n=13;43%),mild lens opacity(n=7;23%),vitreous hemorrhage(n=5;17%)and rhegmatogenous retinal detachment(n=1;3%).No extraocular tumor extension or metastasis occurred.●CONCLUSION:Combined IAC and IVM is effective and safe for the treatment of advanced unilateral retinoblastoma. 展开更多
关键词 intra-arterial CHEMOTHERAPY INTRAVITREAL CHEMOTHERAPY MELPHALAN RETINOBLASTOMA ADVANCED stage UNILATERAL disease
穴位按摩对化疗相关性恶心呕吐干预效果的Meta分析 认领
12
作者 吴婷 黄孟秋 +4 位作者 侯云霞 李佳倩 张青月 庞微 阎玲 《护理管理杂志》 2020年第2期94-98,共5页
目的评价穴位按摩对化疗相关性恶心呕吐的干预效果。方法计算机检索Cochrane图书馆、PubMed、Ovid Medline、EMBASE、Web of Science、维普数据库、中国生物医学文献数据库、中国知网及万方数据库中关于穴位按摩对化疗相关性恶心呕吐干... 目的评价穴位按摩对化疗相关性恶心呕吐的干预效果。方法计算机检索Cochrane图书馆、PubMed、Ovid Medline、EMBASE、Web of Science、维普数据库、中国生物医学文献数据库、中国知网及万方数据库中关于穴位按摩对化疗相关性恶心呕吐干预的随机对照试验,纳入文献质量评价依照Cochrane Handbook(5.1.0)质量评价标准,采用RevMan 5.30软件进行分析。结果共纳入13篇随机对照试验,Meta分析结果显示:穴位按摩可减轻急性恶心呕吐严重程度、延迟性恶心呕吐严重程度、急性恶心呕吐发生率、急性呕吐频率、延迟性恶心频率,但对急性恶心频率、延迟性呕吐发生率和频率的作用效果未显示出优势。结论在常规止吐药物基础之上,联合按摩内关穴可在一定程度上减轻化疗相关性恶心呕吐,同时穴位按摩是一种非侵入性、简单易操作的辅助药物的补充替代疗法,值得临床中推广使用。 展开更多
关键词 化疗 化疗相关性恶心呕吐 穴位按摩 META分析
在线阅读 下载PDF
化疗并发症预警模型在非小细胞肺癌化疗患者中的应用 认领
13
作者 邹凤宇 周昆 +3 位作者 刘霞 李黎 程冬艳 司晴晴 《中华现代护理杂志》 2020年第5期648-652,共5页
目的探讨化疗并发症预警模型在非小细胞肺癌患者化疗期护理中的应用效果。方法采用便利抽样法,选取2016年1月—2019年2月郑州大学第一附属医院胸外科收治的非小细胞肺癌化疗患者106例为研究对象,按照入院时间分为对照组(n=52)和观察组(n... 目的探讨化疗并发症预警模型在非小细胞肺癌患者化疗期护理中的应用效果。方法采用便利抽样法,选取2016年1月—2019年2月郑州大学第一附属医院胸外科收治的非小细胞肺癌化疗患者106例为研究对象,按照入院时间分为对照组(n=52)和观察组(n=54)。对照组给予常规护理,观察组通过化疗并发症预警模型进行护理。采用汉密顿焦虑量表(HAMA)、汉密顿抑郁量表(HAMD)和癌症患者生命质量测定量表(EORTC QLQ-C30)比较两组干预效果,统计两组化疗期间并发症发生情况。结果观察组化疗期间并发症总发生率26.92%(14/52),对照组为46.15%(24/52),差异有统计学意义(χ2=4.147,P<0.05)。干预后3个月,观察组患者HAMA(9.87±4.25)分、HAMD(15.54±3.58)分,均低于对照组,差异均有统计学意义(t值分别为4.738、8.296;P<0.05)。观察组干预后功能评分、症状评分、整体生活质量评分、单项测量项目评分高于对照组,差异有统计学意义(P<0.05)。结论在非小细胞肺癌化疗期间通过化疗并发症预警模型进行护理能够降低患者化疗并发症发生率,缓解患者负性情绪,提高生活质量,值得临床推广应用。 展开更多
关键词 非小细胞肺 化疗 并发症 化疗并发症预警模型
不同病理类型局部晚期(ⅠB2及ⅡA2期)宫颈癌的预后情况分析 认领
14
作者 朱安娜 詹益州 +4 位作者 陈飞燕 李燕 周莉 李从铸 关明飞 《癌症进展》 2020年第8期826-830,共5页
目的探讨不同病理类型局部晚期(ⅠB2、ⅡA2期)宫颈癌的预后情况。方法选取169例ⅠB2、ⅡA2期宫颈癌(鳞状细胞癌149例,腺癌或腺鳞癌20例)患者,根据治疗模式的不同将其分为同期放化疗组、根治性手术组、新辅助化疗+根治性手术组。比较不... 目的探讨不同病理类型局部晚期(ⅠB2、ⅡA2期)宫颈癌的预后情况。方法选取169例ⅠB2、ⅡA2期宫颈癌(鳞状细胞癌149例,腺癌或腺鳞癌20例)患者,根据治疗模式的不同将其分为同期放化疗组、根治性手术组、新辅助化疗+根治性手术组。比较不同病理类型及不同治疗模式局部晚期宫颈癌患者的2年无复发生存率,分析120例接受过根治性手术的局部晚期宫颈癌患者的病理类型与其他临床特征的关系,并比较新辅助化疗+根治性手术组中不同病理类型局部晚期患者对新辅助化疗的反应。结果截至随访结束,随访超过2年者137例,2年无复发生存率为83.9%(115/137),其中,鳞状细胞癌患者的2年无复发生存率高于腺癌或腺鳞癌患者(P﹤0.05)。同期放化疗组、根治性手术组、新辅助化疗+根治性手术组患者的2年无复发生存率分别为77.3%、87.0%、87.2%。接受根治性手术或新辅助化疗后行根治性手术+术后辅助放疗和(或)化疗的120例宫颈癌患者中,肌层浸润情况与局部晚期宫颈癌患者的病理类型可能有关(P﹤0.05)。接受新辅助化疗+根治性手术+术后辅助放疗和(或)化疗的62例患者中,鳞状细胞癌患者58例,包括CR患者14例,PR患者40例,SD患者4例;腺癌/腺鳞癌患者4例,包括CR患者1例,PR患者3例。鳞状细胞癌患者与腺癌/腺鳞癌患者对新辅助化疗的反应比较,差异无统计学意义(P﹥0.05)。结论局部晚期宫颈癌患者的近期预后较好,腺癌或腺鳞癌患者的预后较鳞状细胞癌患者差。对于病理类型为腺癌/腺鳞癌的局部晚期宫颈癌,建议在治疗方式上较鳞状细胞癌更激进,不建议保留卵巢功能,更倾向于以根治性手术为主的综合治疗,可望改善患者预后。 展开更多
关键词 宫颈癌 化学疗法 新辅助化疗 局部晚期宫颈癌 鳞状细胞癌 腺癌 腺鳞癌
在线阅读 下载PDF
护理干预对宫颈癌术后化疗患者依从性及癌因性疲乏的影响 认领
15
作者 杨燕 《中外医学研究》 2020年第8期91-93,共3页
目的:探讨护理干预对宫颈癌术后化疗患者依从性及癌因性疲乏的影响.方法:选取笔者所在医院于2017年1月-2018年5月收治的60例宫颈癌术后化疗患者,按照随机数字表法将其分为对照组和研究组,每组30例.对照组予以常规护理,研究组在对照组基... 目的:探讨护理干预对宫颈癌术后化疗患者依从性及癌因性疲乏的影响.方法:选取笔者所在医院于2017年1月-2018年5月收治的60例宫颈癌术后化疗患者,按照随机数字表法将其分为对照组和研究组,每组30例.对照组予以常规护理,研究组在对照组基础上加以护理干预.比较两组患者心理状态、睡眠质量、化疗依从性及癌因性疲乏.结果:研究组SAS评分、SDS评分、PSQI总分、PFS评分均低于对照组,依从性评分高于对照组,差异均有统计学意义(P<0.05).结论:宫颈癌术后化疗患者采用护理干预可显著改善心理状态、睡眠质量及癌因性疲乏,提升化疗依从性. 展开更多
关键词 宫颈癌 化疗 护理干预 癌因性疲乏 化疗依从性
在线阅读 下载PDF
责任制管理合罗森塔尔效应护理对原发性中枢神经系统淋巴瘤患者化疗不良反应及满意度的影响 认领
16
作者 冷蓉蓉 黄琳 董丽 《中国肿瘤临床与康复》 2020年第1期111-114,共4页
目的探讨责任制管理结合罗森塔尔效应护理对原发性中枢神经系统淋巴瘤(PCNSL)患者化疗不良反应及满意度的影响。方法选取2015年1月至2019年6月间辽宁营口市中心医院收治的62例PCNSL患者,采用随机数字表法分为研究组和对照组,每组31例。... 目的探讨责任制管理结合罗森塔尔效应护理对原发性中枢神经系统淋巴瘤(PCNSL)患者化疗不良反应及满意度的影响。方法选取2015年1月至2019年6月间辽宁营口市中心医院收治的62例PCNSL患者,采用随机数字表法分为研究组和对照组,每组31例。对照组患者采用常规护理干预,研究组患者采用责任制管理结合罗森塔尔效应护理干预,比较两组患者的近期疗效、化疗不良反应和护理满意度。结果研究组患者不良反应总发生率为16.1%,低于对照组的38.7%,差异有统计学意义(P<0.05)。研究组患者近期总有效率为93.5%,优于对照组的74.2%,差异有统计学意义(P<0.05)。研究组患者护理满意度为90.3%,优于对照组的67.7%,差异有统计学意义(P<0.05)。结论责任制管理结合罗森塔尔效应护理可明显减少PCNSL患者不良反应,提高临床疗效及护理满意度,值得临床运用。 展开更多
关键词 责任制管理 罗森塔尔效应护理 原发性中枢神经系统淋巴瘤 药物疗法
益生菌对结直肠癌化疗患者营养状况、炎性反应及化疗相关并发症的影响 认领
17
作者 陈秋霞 朱江丽 徐毅 《健康研究》 CAS 2020年第1期68-71,共4页
目的探讨复合益生菌对结直肠癌化疗患者营养状况、炎性反应及相关并发症的影响,寻求适宜结直肠癌化疗患者的营养评估方法。方法选取符合标准的需要化疗的结直肠癌患者98例,随机分为对照组及观察组。2组患者使用相同的化疗方案治疗一周期... 目的探讨复合益生菌对结直肠癌化疗患者营养状况、炎性反应及相关并发症的影响,寻求适宜结直肠癌化疗患者的营养评估方法。方法选取符合标准的需要化疗的结直肠癌患者98例,随机分为对照组及观察组。2组患者使用相同的化疗方案治疗一周期,常规护理,观察组在化疗的同时给予复合益生菌。观察2组化疗相关并发症的发生情况,及治疗前后2组患者营养状况、炎性反应的变化情况。结果PG-SGA、NRS2002、BMI、ALB、PA结果显示,患者营养不良发生率分别为57.1%、39.8%、19.4%、24.5%、32.7%。与治疗前相比,治疗后2组患者PG-SGA、NRS2002及PA得到显著改善,且观察组PG-SGA及PA改善情况优于对照组,差异均有统计学意义(P<0.05)。治疗期间,观察组恶心、呕吐、腹泻及食欲降低发生情况都低于对照组;化疗后,两组患者hs-CRP均下降,差异均有统计学意义(P<0.05)。与对照组相比,观察组CD4^+细胞比例显著升高,CD8^+细胞比例显著下降,CD4^+/CD8^+比值显著升高,差异均有统计学意义(P<0.05)。结论PG-SGA营养不良检出率较高,适用于结直肠癌患者营养状况评价。复合益生菌可以改善化疗患者营养状况,增强患者免疫力,降低化疗相关并发症的发生。 展开更多
关键词 结直肠癌 化疗 益生菌 炎症反应
在线阅读 下载PDF
老年食管鳞癌患者单纯放疗和同步放化疗的有效性和安全性比较 认领
18
作者 周彬 傅辰春 +1 位作者 孙新臣 孙向东 《临床肿瘤学杂志》 CAS 北大核心 2020年第2期161-166,共6页
目的比较老年食管鳞癌患者(年龄≥65岁)单纯放疗(RT)和同步放化疗(CCRT)的有效性和安全性。方法收集2010年1月至2016年12月于本院首程接受根治性放疗的122例老年食管鳞癌患者,根据治疗情况分为RT组81例和CCRT组41例(替吉奥单药23例、奈... 目的比较老年食管鳞癌患者(年龄≥65岁)单纯放疗(RT)和同步放化疗(CCRT)的有效性和安全性。方法收集2010年1月至2016年12月于本院首程接受根治性放疗的122例老年食管鳞癌患者,根据治疗情况分为RT组81例和CCRT组41例(替吉奥单药23例、奈达铂单药2例、雷替曲塞联合奈达铂7例和多西他赛联合奈达铂5例),采用实体瘤疗效评价标准RECIST 1.1版评价近期疗效,药物毒性反应标准NCI-CTC 4.0版评价药物毒副反应,急性放射反应评分标准(RTOG/EORTC)评价放疗毒副反应,根据随访数据进行预后分析并采用Cox比例风险回归模型进行多因素分析。结果RT组的总有效率和疾病控制率分别为84.0%和98.8%,与CCRT组92.7%和100.0%的差异无统计学意义(P>0.05)。RT组的中位无进展生存期(PFS)和总生存期(OS)分别为16.1个月和23.8个月,与CCRT组19.7个月和27.1个月的差异无统计学意义(P>0.05)。单因素分析显示影响PFS的因素包括ECOG评分、T分期和放疗剂量,影响OS的因素包括ECOG评分、T分期、N分期、临床分期和放疗剂量,多因素分析显示ECOG评分和放疗剂量是影响PFS的独立预后因素,而ECOG评分和N分期是影响OS的独立预后因素。最常见急性不良反应为放射性食管炎和骨髓抑制(多为1~2级),RT组未发生3~4级不良反应,CCRT组3~4级急性放射性食管炎、放射性肺炎和骨髓抑制的发生率升高至7.3%(3/41)、9.6%(4/41)和7.3%(3/41),差异均有统计学意义(P<0.05)。结论老年食管鳞癌行根治性放疗,放疗剂量提高至60~65 Gy,患者耐受性良好,可延长生存并提高生活质量。是否同步放化疗应综合评估后慎重选择。 展开更多
关键词 食管鳞癌 放疗 化疗 老年
在线阅读 下载PDF
综合疗法在肺癌患者化疗后便秘中的应用 认领
19
作者 王浩 《中国肛肠病杂志》 2020年第1期48-49,共2页
为观察综合疗法在肺癌患者化疗后便秘中的应用效果,将48例肺癌化疗后便秘患者随机分为常规组和综合疗法组,每组24例。常规组给予一般治疗,综合疗法组给予综合疗法治疗,比较2组患者治愈率,大便质地变软时间、排便不费力时间;治疗前后便... 为观察综合疗法在肺癌患者化疗后便秘中的应用效果,将48例肺癌化疗后便秘患者随机分为常规组和综合疗法组,每组24例。常规组给予一般治疗,综合疗法组给予综合疗法治疗,比较2组患者治愈率,大便质地变软时间、排便不费力时间;治疗前后便秘症状积分以及肺癌患者生存质量测定量表(FACT-L)分值。结果显示,综合疗法组患者在治愈率、大便质地变软时间、排便不费力时间、便秘症状积分以及患者生存质量方面均优于常规组(P<0.05)。结果表明,综合疗法用于肺癌患者化疗后便秘中效果确切,可有效改善患者排便情况,缩短治疗时间,提高患者生存质量,值得临床推广应用。 展开更多
关键词 便秘 综合疗法 肺癌 化疗
恶性肿瘤营养支持新进展 认领
20
作者 汤海涛 卢俊 +1 位作者 高娜 孙迪文 《临床普外科电子杂志》 2020年第1期9-14,共6页
恶性肿瘤患者是营养不良高危人群,营养不良影响患者生活质量,降低肿瘤治疗有效性,增加化疗毒副作用,致使肿瘤治疗周期不足或中断,影响生存及预后,恶性肿瘤营养不良发生率为40%~80%。肿瘤化疗患者及早给予营养风险筛查,提供有效营养支持... 恶性肿瘤患者是营养不良高危人群,营养不良影响患者生活质量,降低肿瘤治疗有效性,增加化疗毒副作用,致使肿瘤治疗周期不足或中断,影响生存及预后,恶性肿瘤营养不良发生率为40%~80%。肿瘤化疗患者及早给予营养风险筛查,提供有效营养支持,提高肿瘤患者对放化疗治疗耐受力、敏感性及顺应性,改善生活质量、延长生存期等方面具有重要意义。 展开更多
关键词 恶性肿瘤 化疗 营养风险 营养支持
在线阅读 下载PDF
上一页 1 2 250 下一页 到第
使用帮助 返回顶部 意见反馈